ONE Bio

ONBI

Biotechnology · Healthcare

Price

$0.00

+0.00 (+0.00%)

Market Cap

$4,236

Winston Score

Winston is curious

Mixed quality — meaningful strengths and weaknesses.

Share count rising — dilution

+9516.8% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 67K (2006) → 6.4M (2010)

ONE Bio Corp. is a small biotechnology company focused on developing biological and bio-based products. Biotechnology companies like this one use living organisms or biological processes to create products for industries such as healthcare, agriculture, or industrial applications. With a market cap near zero, ONE Bio Corp. is a micro-cap company in the early stages of building its business.

The company generates revenue across its product lines, reflected in a gross margin of roughly 38%, which suggests it retains a meaningful portion of each dollar it earns after direct costs. Its operating margin of about 26% indicates it is currently covering operating expenses, which is uncommon for small biotech firms. The main risk for a company this size is limited financial resources, which can make it difficult to fund research, scale operations, or compete against larger, better-funded rivals in the biotechnology space.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+0.3% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-25.8% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$259,878/ year

↓ Declining (-31% vs prior year)

0.5% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

7.5%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$14M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

ONE Bio is growing revenue at 0% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

42.5%

Healthy — 42.5% gross margin

Operating Margin

22.7%

Excellent — 22.7% operating margin

ROCE

4.1%

Weak — 4.1% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+6.1%

Slow sales growth (6.1% YoY)

EPS YoY

-38.9%

Earnings shrinking (-38.9% YoY)

Earnings per share down more than 10%. Either a bad year, or a real decline.

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

127%

Turns 127% of profit into real cash

FCF Margin

13.0%

Converts sales into free cash efficiently (13.0%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.53

Conservative — low debt load (0.53)

Interest Cover

11.14x

Comfortably covers interest (11.1x)

Interest coverage above 8. Profits cover interest many times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

0.0x

Attractive valuation — P/E 0.0

P/E under 10. The price tag is small relative to last year's profit.

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial